Quantitative Radiology Solutions (QRS), a privately-held company that enables body-wide analysis of medical images to personalize cancer treatment decisions, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Automatic Anatomy Recognition (AAR) technology for use in radiation treatment planning. AAR is a software-only medical device that automatically processes CT studies to produce contours for organs-at-risk during the treatment planning process. Designed to work independently of a specific treatment planning system, AAR is deployed on a cloud-based platform.
“FDA clearance for AAR in radiation treatment planning is a major milestone in our mission to personalize cancer treatment decisions through automated analysis of medical images,” said Joe Camaratta, President and CEO of QRS. “Our clinical evaluation at 4 radiation treatment centers demonstrated that AAR improves the accuracy and consistency of OAR contouring, and reduces the time required for treatment planning.”
QRS is a PCI Ventures Penn spinout company.